Company: NCNA
Filing Date: 2025-05-02
Form Type: F-1/A
Source: 0001193125-25-110310
Chunk: 10

Company: NuCana plc
Filing Date: 2025-05-02
Form: F-1/A
Chunk 10
---
, financial condition, results of operations and prospects
may have changed since that date.

This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our
securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of
this prospectus applicable to those jurisdictions.

Unless otherwise indicated or the context otherwise requires, in this prospectus,
“NuCana,” “NuCana plc,” the “Company,” “we,” “us” and “our” refer to NuCana plc and its consolidated subsidiaries. See “Description of Share Capital.”

This prospectus and the information incorporated by reference herein and therein contains references to trademarks, trade names and service
marks belonging to us or other entities. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the or TM symbols, but such
references are not intended to indicate, in any way, that the applicable owner will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies’
trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, trade names, and service marks included or incorporated by reference into this prospectus are the
property of their respective owners.

1

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere in this prospectus and in the documents incorporated by reference herein. It may not contain all of the information that may be important to you. Before investing in our securities, you should read this entire prospectus and information incorporated by reference into this prospectus, including the financial statements and related notes and “Risk Factors” starting on page 8 of this prospectus, carefully for a more complete understanding of our business and this offering.

The Company

We are a clinical-stage
biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTidetechnology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer